Hong Kong has world-class universities, deep capital markets and some of the most densely packed hospital talent in Asia. What it has never quite had is a medical-technology industry to match. A four-part South China Morning Post series asks whether that is finally changing, touring the laboratories where researchers are building high-speed diagnostic chips, surgical robots and AI-driven treatment tools. The ambition, as the series frames it, is nothing less than becoming a “Silicon Valley of the East” for healthcare. The obstacles, it makes equally clear, are money, manufacturing and the long road from a working prototype to a product a hospital will actually buy.
The question is not whether the science is real — on the evidence of the past two years, it plainly is. Hong Kong teams have produced a string of results that would flatter any research hub on earth. The harder question is whether a city built on finance and property can learn the slower, messier business of turning discoveries into companies. That tension, between laboratory brilliance and commercial follow-through, runs through every part of the series. It is also what makes Hong Kong’s experiment worth watching for anyone interested in where medical innovation happens next.
Robots Smaller Than a Grain of Rice
Start with the machines. Engineers at the Hong Kong University of Science and Technology have built what they describe as the world’s smallest multifunctional surgical robot: a device 0.95 millimetres across, some 60 percent smaller than existing endoscopic robots. It combines imaging, high-precision motion and multiple functions — sampling, drug delivery and laser ablation — in a single hollow-skeleton body threaded with an optical-fibre array. In laboratory tests it widened the imaging field dramatically and detected obstacles well beyond previous theoretical limits. Lead researcher Professor Shen Yajing argues that solving this “impossible trinity” of size, vision and function opens the way to diagnosis and treatment in parts of the body that today’s instruments simply cannot reach, with in-vivo trials the next step.
Across the harbour of academia, a Chinese University of Hong Kong team led by Professor Zhang Li has tackled the companion problem: knowing where a tiny robot is once it is inside a patient. Their AI-powered magnetic tracking system follows millimetre-scale wireless medical robots in real time, achieving millimetre-level accuracy at depths of up to ten centimetres in tissue, even amid the magnetic interference of a working clinical environment. Published in Science Robotics, the work was validated in animal tests that steered micro-robots through the spinal canal and bile duct. Tracking sounds like a footnote to robotics; in practice it is the difference between a laboratory curiosity and a tool a surgeon can trust.
From the Laboratory to the Operating Theatre
Hong Kong’s flagship bet on this translation problem is the Multi-Scale Medical Robotics Center, part of the government’s InnoHK research clusters, where medicine and engineering faculty work on endoluminal robots, magnetically guided endoscopes and image-guided surgical platforms under one roof. The centre has already produced a demonstration with genuine symbolic weight: an intercontinental telesurgery exercise in which specialists in Shanghai and London remotely operated a robotic platform hosted in Hong Kong on a live model, in real time. CUHK’s Professor Philip Chiu framed the point explicitly — Hong Kong sits at the heart of Asia, and the exercise showcased the city as the connective tissue between world-class surgical teams. Two local medical students took part, and nearly 200 secondary school students watched, a deliberate investment in the talent pipeline.
The commercial proof point arrived from the private market. Cornerstone Robotics, a Hong Kong surgical-robotics company founded by Professor Kwok Wai Samuel Au, drew a strategic investment of roughly US$700 million from Medtronic, the global medical-device giant, which also took distribution rights for Cornerstone’s Sentire surgical system in markets outside the United States. Sentire had already won approval from China’s National Medical Products Administration in 2024, and in May 2026 added a European CE Mark and Singapore approval covering general, gynaecological, thoracic and urological procedures. A Hong Kong-designed robot, approved on three regulatory regimes and backed by the industry’s largest player, is exactly the trajectory the city’s planners describe. It is also, so far, the exception rather than the rule.
The Valley Between Discovery and Product
The SCMP series is candid about why such cases remain rare. Hong Kong researchers compete well for grants and publications, but private investment in local medical technology is thin, and the city’s near-total lack of manufacturing means prototypes must be built elsewhere — usually across the border in Shenzhen and the Greater Bay Area. Commercialisation expertise, from regulatory strategy to clinical-trial management to hospital procurement, is scarce and expensive. A diagnostic chip that performs beautifully in a university laboratory still faces years of validation before a single patient benefits. Many Hong Kong inventions have historically been sold, licensed or simply lost at precisely this stage.
Artificial intelligence is the newest front in the same contest. The Centre for Artificial Intelligence and Robotics in Hong Kong has unveiled systems such as the CARES multimodal clinical AI agent, alongside diagnostic agents, ultrasound foundation models and an embodied-intelligence operating room, presented to hospital leaders from Hong Kong and Shenzhen at its CREATE Symposium. The pitch is end-to-end: AI that assists diagnosis, guides robots and supports surgery, developed where the patients and clinicians are. Whether hospitals adopt such systems at scale will depend less on demonstrations than on evidence, liability frameworks and budgets. Those are unglamorous determinants, but they decide which technologies survive.
What Success Would Look Like
Hong Kong does hold structural cards few rivals can match. It offers common-law intellectual-property protection, internationally recognised universities and hospitals, free movement of capital, and a position inside China’s vast healthcare market without being wholly of it — a combination neither Singapore nor Shenzhen can replicate exactly. An ageing population across the region guarantees demand for exactly the minimally invasive, AI-assisted, robot-delivered care its laboratories are building. If the Greater Bay Area supplies manufacturing scale while Hong Kong supplies research, regulation and finance, the “frontier medicine centre” stops being a slogan. The next few years will show whether more Cornerstone-style deals follow, or whether the valley between discovery and product keeps claiming the city’s best ideas. On the laboratory evidence alone, the raw material for success is already there.
Source: South China Morning Post
